There is no great treatment for liver cancer. AF knows this. The Delcath product is a delivery system that will be significant for a number of companies treating a variety of conditions.
The treatment thesis is to isolate the organ in question, saturate it with the selected treatment agents, then filter out what would be toxic levels of drugs and return organ functionality to the patient.
This is clearly a treatment that will enable specific, high levels of medicines to be delivered where they are needed without the systemic toxicity typically associated with past treatment techniques.
One has to wonder why a knowledgeable reporter might write such a piece at this particular time, in what seems to be conjunction with a timely effort to knock down the stock price through media and stock dumps.
This drug delivery methodology has a significant possibility of becoming the "standard of care" allowing many companines a pathway to test, then deliver a large number of cancer drugs.
I don't pretend to know the outcome here, but I wouldn't mind seeming some of the sellers playing "dirty" get pounded. I think there is that chance here.
We will see how able they are to scare shareholders out of their positions.
Adam F'erstein is always "against" any innovative or new treatment no matter how effective it is. He is a paid schill for the big pharma companies who bashes small biotechs consistently. You can safely ignore anything he says.
Laertes - Well said! Thoughtful post....provokes a curiosity re:Mr Feuerstein's offerring! Charles Limmer - New York Incidentally,I just finished mounting a perfect pair of Prepona laertes (Nymphalidae).